Emmaus Life Sciences to Present Phase 3 Sickle Cell Disease Trial Data at 56th American Society of Hemotology Annual Meeting

Reduction in the Frequency of Sickle Cell Crisis, Frequency in Hospitalizations, Hospital Days and Fewer Cases of Acute Chest Syndrome Highlighted in Abstract

Vaccine Holds Hope of Preventing Antibiotic Resistant Skin Infections

MRSA under a microscope

LA BioMed Researchers Find Novel NDV-3 Vaccine Protects Against MRSA

LOS ANGELES – (Dec. 8, 2014) – In the U.S. and around the globe, skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus (MRSA) continue to endanger the health and lives of patients and otherwise healthy individuals. Treatment is difficult because MRSA is resistant to many antibiotics, and the infections can recur, placing family members and other close contacts at risk of infection.